Format

Send to

Choose Destination
Autoimmune Dis. 2014;2014:731806. doi: 10.1155/2014/731806. Epub 2014 Jan 16.

Rituximab for remission induction and maintenance in refractory systemic lupus erythematosus.

Author information

1
Rheumatology Unit, Fundación Valle del Lili, ICESI University, Carrera 98 18-49, Cali, Colombia.
2
Internal Medicine Unit, Fundación Valle del Lili, CES University, Cali, Colombia.
3
Clinical Research Unit, Fundación Valle del Lili, Cali, Colombia.
4
School of Statistics, Universidad del Valle, Cali, Colombia.

Abstract

Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease with high morbidity if untreated. Sometimes, despite aggressive treatments, the disease remains active with cumulative organic damage. We conducted a retrospective and descriptive observational study of patients with SLE refractory to conventional treatment who were treated with rituximab (RTX) as remission induction therapy and maintenance. There was a significant reduction in the conventional immunosuppressive drug dose and the number of relapses of disease. RTX appeared to be effective and safe for the induction and maintenance of remission in patient with SLE refractory to conventional treatment.

Supplemental Content

Full text links

Icon for Hindawi Publishing Corporation Icon for PubMed Central
Loading ...
Support Center